| Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung D Chen, J Liu, J Wu, JS Suk Expert opinion on drug delivery 18 (5), 595-606, 2021 | 57 | 2021 |
| An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma M Tian, AT Cheuk, JS Wei, A Abdelmaksoud, HC Chou, D Milewski, ... The Journal of Clinical Investigation 132 (16), 2022 | 38 | 2022 |
| AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis ML Hirsch, LM Conatser, SM Smith, JH Salmon, J Wu, NE Buglak, ... Scientific Reports 7 (1), 17840, 2017 | 31 | 2017 |
| A two‐pronged pulmonary gene delivery strategy: a surface‐modified fullerene nanoparticle and a hypotonic vehicle D Chen, S Liu, D Chen, J Liu, J Wu, H Wang, Y Su, G Kwak, X Zuo, D Rao, ... Angewandte Chemie International Edition 60 (28), 15225-15229, 2021 | 17 | 2021 |
| Differential Impacts of HHV-6A versus HHV-6B Infection in Differentiated Human Neural Stem Cells E Bahramian, M Furr, JT Wu, RM Ceballos Frontiers in Immunology 13, 847106, 2022 | 5 | 2022 |
| Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma M Tian, JS Wei, N Shivaprasad, SL Highfill, BE Gryder, D Milewski, ... Cell Reports Medicine, 2023 | 3 | 2023 |
| Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma JT Wu, A Cheuk, K Isanogle, C Robinson, X Zhang, M Ceribelli, E Beck, ... Cancers 15 (16), 4034, 2023 | 2 | 2023 |
| 319. Rationally Designed AAV Inverted Terminal Repeats Enhance Gene Targeting M Hirsch, J Wu Molecular Therapy 24, S129, 2016 | 2 | 2016 |
| Abstract LB042: A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4 M Tian, K Jia, JT Wu, JS Wei, AT Cheuk, Z Zhang, EG Pope, B Shor, ... Cancer Research 84 (7_Supplement), LB042-LB042, 2024 | | 2024 |
| Abstract LB315: Inhibition of FGFR4 with futibatinib combined with inhibition of IGF1R, Src family kinases, or AKT is synergistic against rhabdomyosarcoma J Wu, A Cheuk, JS Wei, Y Kim, D Milewski, X Zhang, M Ceribelli, E Beck, ... Cancer Research 83 (8_Supplement), LB315-LB315, 2023 | | 2023 |
| FGFR4 and CD276 dual targeting CAR T cells demonstrate synergistic antitumor activity in childhood rhabdomyosarcoma M Tian, JS Wei, A Cheuk, D Milewski, Z Zhang, YY Kim, C Liu, S Badr, ... Cancer Research 83 (7_Supplement), 1784-1784, 2023 | | 2023 |
| Abstract LB213: Potent antitumor activity of a FGFR4 CAR-T in rhabdomyosarcoma ATC Cheuk, M Tian, N Shivaprasad, S Highfill, D Milewski, GT Brown, ... Cancer Research 82 (12_Supplement), LB213-LB213, 2022 | | 2022 |
